- |||||||||| CS3002 / CStone Pharma
Journal: First report of leaf spot on Chaste-Tree Caused by Alternaria alternata in China. (Pubmed Central) - Aug 15, 2023
The multigenes phylogenetic analysis revealed that isolate Aa1 and Alternaria alternata TCS3002 + CBS 916.96 clustered within the same clade with 99% bootstrap support...2020) to cause leaf spot. To our knowledge, this is the first report of A. alternata causing leaf spot disease on chaste-tree and provides an important reference for further biology and epidemiology research.
- |||||||||| CS3002 / CStone Pharma
Enrollment change, Trial completion date, Trial termination, Trial primary completion date, Metastases: A Study of CS3002 in Subjects With Advanced Solid Tumors (clinicaltrials.gov) - Apr 22, 2021
P1, N=10, Terminated,
To our knowledge, this is the first report of A. alternata causing leaf spot disease on chaste-tree and provides an important reference for further biology and epidemiology research. N=46 --> 10 | Trial completion date: Feb 2022 --> Feb 2021 | Recruiting --> Terminated | Trial primary completion date: Nov 2021 --> Feb 2021; The study has been stopped for strategic and business reasons.
- |||||||||| CS3002 / CStone Pharma
Enrollment open, Metastases: A Study of CS3002 in Subjects With Advanced Solid Tumors (clinicaltrials.gov) - Mar 10, 2020
P1, N=46, Recruiting,
Given the encouraging preclinical properties as well as the unique potential in allowing indication expansion and delaying drug resistance to CDK4/6 inhibition, CS3002 is selected for clinical exploration in a Phase 1 study for advanced solid tumors (NCT04162301). Not yet recruiting --> Recruiting
|
